ALLY vs GSK · P/E 65, rev $2.29B vs P/E 13, $103.31B cap
Ally Financial Inc (ALLY) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Ally Financial Inc (ALLY) is a credit services company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported ALLY revenue for 2026-06-30 was $2.29B. Net income was $410.0M. Revenue was up 8.8% from 2026-03-31 to 2026-06-30. ALLY currently screens at market cap $11.95B and trailing P/E 64.8.
GSK does not have a complete income-statement cache yet.
ALLY currently screens at market cap $11.95B and trailing P/E 64.8. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the ALLY and GSK stock pages for the full models.
Not investment advice.